About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNANCT00822991

Sonazoid Enhanced Liver Cancer Trial for Early Detection

The aim of this study is to prove usefulness of contrast-enhanced ultrasound (CE-US) using Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound (B-mode US) for h...

Lead sponsor: Kindai University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Masatoshi Kudo, professor

CONTACT

+81-72-366-0221 m-kudo@med.kindai.ac.jp

Kazuomi Ueshima, lecturer

CONTACT

+81-72-366-0221 kaz-ues@med.kindai.ac.jp

Sponsors

Lead Sponsor

Kindai University

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Age over 20
•2. HBV or HCV related liver cirrhosis
•3. No history of HCC
•4. Diagnosed as liver cirrhosis histologically or clinically Histologically confirmed by liver biopsy Confirmed by formula of diagnosing cirrhosis Radiological finding Finding of portal hypertension Platelet\<130,000
•5. Inpatient or outpatient
•6. Patients who signed a written informed consent form

Exclusion Criteria

•1. History of hypersensitivity to egg yolk
•2. Pregnant or lactating women and women who may be pregnant
•3. Severe liver dysfunction(AST, ALT,or BIL level \>10ULN
•4. Associated with HCC
•5. Patients receiving interferon
•6. Age under 20
•7. Judged by investigator not to be appropriate for inclusion in this study

Related studies

RECRUITINGPhase 2

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT06902246 · Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma

RECRUITINGPhase 2

A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis

NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis

RECRUITINGPhase 2

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

NCT07175441 · Advanced Unresectable Hepatocellular Carcinoma

RECRUITINGPhase 2

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

NCT07422753 · Hepatocellular Carcinoma (HCC)

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

NCT07439939 · Liver Cirrhosis, Portal Hypertension

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 30, 2010Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment760

Start dateJan 2009

Last updatedDec 30, 2010

Condition

Hepatocellular Carcinoma Liver Cirrhosis Hepatitis B Hepatitis C

Locations shown

Kinki University School of Medicine, Department of Gastroenterology and Hepatology

Ōsaka-sayama, Osaka

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 30, 2010Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions